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Renal hemodynamic effects of therapeutic plasma levels of sulindac
sulfide during hemorrhage. There is continued debate over any renal-
sparing effects of sulindac (S): such a property would be of benefit and
be unique among nonsteroidal anti-inflammatory drugs (NSAIDS). S
undergoes a distinct metabolism whereby the active drug (sulindac
sulfide (SS) ) does not appear in the urine. Accordingly, we tested the
effect of a plasma concentration of SS in the therapeutic range on renal
blood flow (RBF), glomerular filtration rate (GFR), and renal
prostaglandin (P0) concentrations during sudden renal isehemic stress.
The ischemic stress was produced by a 15 to 20% reduction in arterial
pressure by arterial hemorrhage (H) in four separate groups of anesthe-
tized dogs: control, SS (0.4 mg/kg i.v. bolus followed by 0.03 mg/kg/mm
constant infusion), indomethacin (I, 10mg/kg), and benoxaprofen (B, 75
mg/kg). A plasma concentration of 3.69 tg/ml of SS was achieved by
the infusion, and no SS appeared in the urine. H reduced GFR (by 46%)
and RBF (by 38%) in control dogs; in SS-treated dogs, a 60% decline in
GFR and a 73% decrease in RGF occurred. These decreases in renal
hemodynamics in the SS group during H were significantly greater than
in the control group. Further, these decrements in GFR and RBF were
similar to those observed in the I- and B-treated dogs. Finally, SS
reduced baseline arterial and renal PG concentrations, and prevented
any increase in renal PG release during H. Thus, we conclude that a
concentration of SS in the therapeutic range, which does not appear in
the urine, is capable of enhancing the decline in GFR and RBF during
a sudden ischemic stress such as H.
Nonsteroidal anti-inflammatory drugs (NSAIDS) now occupy
a central place in clinical therapeutics, having become among
the most widely prescribed class of drugs in the United States.
Along with the accepted efficacy and utility of these agents in
the treatment of a variety of conditions has developed a growing
awareness that renal insufficiency may develop in a subset of
vulnerable patients [1—8]. The individuals who are most likely to
experience renal insufficiency upon exposure to the NSAIDS
typically do so in the context of renal ischemia, a condition
usually characterized by high rates of prostaglandin synthesis
and release [1, 3, 9]. In fact, renal hemodynamics have been
shown experimentally to be largely dependent on the vasodila-
tory, moderating influence of prostaglandins (most notably,
prostacyclin) during several renal ischemic stress states
[10—18].
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In view of the frequency with which renal underperfusion (for
example, heart failure, liver disease, or renal disease) is en-
countered in patients in need of an NSAID, the development of
an NSAID that does not perturb renal function would be of
obvious therapeutic benefit. In this regard, sulindac has been
reported to not reduce renal function further in several groups
of susceptible patients [19—22]. This protective effect of
sulindac has been related to the unusual metabolism of the drug.
It is converted from an inactive sulfoxide to an active sulfide in
the liver and kidney [22—27]. This active form is rapidly recon-
verted to the inactive sulfoxide by mixed-function oxidases in
the kidney. The inactive sulfoxide and further oxidation prod-
uct, the sulfone, are the metabolites usually excreted by the
kidney, and the sulfide form does not appear in the urine.
Despite this unusual metabolic pathway and the reports of a
renal-sparing effect of the drug, controversy still exists regard-
ing its ability to inhibit prostaglandin synthesis [28—31]. Accord-
ingly, we performed the following experiments to test further
the effects of sulindac on the kidney. To do this, we infused
sulindac sulfide systemically into dogs which then underwent a
renal ischemic stress induced by hemorrhage. The plasma
concentration of the sulindac sulfide approximated that seen
after a usual 200 mg dose of the drug in humans, and no sulfide
was detected in urine. The results demonstrate that a therapeu-
tic plasma level of sulindac sulfide may further enhance a renal
ischemic stress.
Methods
The preparations used in this model of hemorrhage have been
described in detail previously [32]. Briefly, 20 mongrel dogs
weighing between 20 and 30 kg were used in the study; food but
not water was withheld the day prior to the study. On the day
of the study, the dogs were anesthetized with pentobarbital (25
to 30 mg/kg), intubated, and ventilated with a Harvard respira-
tor. Supplemental small doses of pentobarbital were given as
needed to maintain an even state of anesthesia. Polyethylene
catheters were placed in both ureters and renal veins through
flank incisions and a retroperitoneal approach. A brachial artery
catheter attached to a Statham transducer (Statham Instru-
ments, Oxnard, California, USA) and a Hewlett Packard 7712
recorder (Elkhart, Indiana, USA) was used to monitor arterial
pressure. Midway through surgery, a 0.5% sodium chloride
infusion was begun through a peripheral vein at a rate of 12
ml/min to replace fluid losses and achieve stable urine flows.
484
Sulindac sulfide plasma levels during hemorrhage 485
This infusion was continued for 60 mm, after which it was
reduced to equal urine flow rates for the remainder of the study.
After the surgery had been completed, an infusion (0.5 mllmin)
of para-aminohippurate (PAH) and inulin was begun to maintain
the plasma levels of these substances at 1 to 3 mgldl and 15 to
20 mg/dl, respectively.
The animals were allowed to stabilize for 1 to 1.5 hr after
surgery. Urine samples for inulin, PAH, and sulindac sulfide
were obtained during several timed 5- to 10-mm collections
during each collection period; blood samples for inulin, PAH,
6-keto-PGF1a, and sulindac sulfide were obtained at the mid-
point of the urine collections. Urine and blood samples for
inulin and PAH were analyzed on a Technicon II autoanalyzer
(Technicon Instruments, Tarrytown, New York, USA). Calcu-
lations used for inulin clearance (GFR) and PAR extraction
(RBF) were performed as described previously [331. Arterial
and renal venous blood samples for 6-keto-PGF1a (the stable
metabolite of prostacyclin) were obtained in duplicate at the
midpoint of each collection period. The samples were collected
on ice in tubes containing heparin (100 U/ml) and indomethacin
(1 g/ml). The blood was centrifuged at 4°C, and the plasma was
removed and stored at —20°C until assayed. The plasma was
analyzed for 6-keto-PGF1a as described previously [34]. This
method involves extraction of the plasma, purification by silicic
acid chromatography, and quantification by RIA. The RIA used
a specific antibody developed in our laboratory that cross
reacted 2% with PGE, 14% with PGF1a, and less than 0.67%
with other known PGs or PG metabolites.
The doses of indomethacin (10 mg/kg i.v.) and benoxaprofen
(75 mg/kg i.v.) were selected because these doses reliably
reduce endogenous renal PG synthesis [35, 36]. The goal of the
studies was to compare the known pharmacologic effect of
indomethacin and benoxaprofen (in higher doses) to the effect
of sulindac sulfide in therapeutic doses. Thus, the dose of
sulindac sulfide infused into the sulindac group (see below) was
designed to approximate the plasma levels of the sulfide (2 to 3
gIml) achieved after a usual 200 mg dose of the prodrug,
sulindac sulfoxide, to humans [37]. Preliminary studies were
performed in three dogs to determine the appropriate dose; a
bolus of 0.4 mg/kg of sulindac sulfide was initially given,
followed by a constant infusion (0.5 mllmin) of 0.03 mg/kg/mm
for the duration of the study.
Plasma and urine samples were measured for sulindac sulfide,
sulfoxide, and sulfone by high performance liquid chromatog-
raphy using a modification of methods described previously
[37]. Briefly, 200 pL of plasma or urine are added to internal
standard (indomethacin) and either acetonitrile or dichlorometh-
ane samples are vortexed and centrifuged and the aqueous
phase aspirated and discarded. The organic phase is evaporated
to dryness under nitrogen followed by reconstitution in 150 sL
of solvent (either ethanol alone or with 25% acetonitrile).
Samples are injected onto two C18 radial compression modules
(Waters Associates, Milford, Massachusetts, USA). Gradient
elution is employed at a flow rate of 1.5 mllmin with a
Perkin-Elmer Series 3B (Norwalk, Connecticut, USA). The
gradient consists of acetonitrile increasing from 40 to 65% over
33 mm with 0.05 M potassium phosphate buffer at pH 3.0.
Detection is effected with a Perkin-Elmer LC-65T variable
wavelength detector at 265 flM. Detection times are approxi-
mately 13, 16, 20, and 27 mm for sulindac sulfoxide, sulindac
sulfone, indomethacin, and sulindac sulfide, respectively. The
within assay (N = 8) coefficients of variation ranged from 5.7 to
16.3% at concentrations of 3.0 and 0.2 g/ml sulindac sulfide,
respectively. Between assay (N = 8) coefficients of variation
were 15 and 31% at the same concentrations. Hence, 0.2 jsg/ml
represents a qualitative limit of detection.
Clearance periods
Four clearance periods were incorporated into the protocol,
as follows:
Period 1 (Control): Baseline clearance measurements and
plasma levels were obtained.
Period 2 (Drug infusion): Fifteen mm prior to the beginning of
this period, the four groups of animals were treated as follows:
Control (N = 5), received a bicarbonate solution as an i.v. bolus
equal in volume to the solutions containing prostaglandin syn-
thesis inhibitors; Indomethacin (N = 5), indomethacin (10
mg/kg) by i.v. bolus; Benoxaprofen (N = 5), benoxaprofen (75
mg/kg) by i.v. bolus; Sulindac (N = 5), sulindac sulfide 0.4
mg/kg by i.v. bolus followed by a constant infusion of 0.03
mg/kg/mm to maintain steady-state plasma concentrations of
the drug within the therapeutic range.
Period 3 (Hemorrhage): All four groups of animals were
hemorrhaged via the arterial catheter to a stable mean arterial
blood pressure that was 15 to 20% less than the mean blood
pressure in Period 2. The hemorrhage was performed over 10
mm and two to three urine collection periods lasting 10 to 15
mm were then performed.
Period 4 (Post control): Thirty to 40 mm after reinfusion of
the shed blood, a post-control collection was made.
Statistical analysis was performed by Scheffe's analysis of
variance procedure [38] when making comparisons between
periods and groups. All data are expressed as the mean SEM,
and a P value of <0.05 was considered significant.
Results
Effects of hemorrhage on systemic hemodynamics (Table 1)
Each group had a similar decline in mean blood pressure
(MBP) during the hemorrhage period. The percentage of reduc-
tion in MBP for each group was: 17% for control, 19% for
indomethacin, 23% for benoxaprofen, and 19.5% for sulindac.
The mean amount of blood removed from each group (in mi/kg)
to cause this reduction in blood pressure was similar for each
group: control 21.7; indomethacin 20.7; benoxaprofen 18.2; and
sulindac 17.6. The hemorrhage caused an equivalent 2% de-
crease in hematocrit in each group. Following the i.v. infusion
of benoxaprofen, a significant increase in MBP and decline in
heart (HR) occurred. Mild to moderate hemolysis occurred
after the benoxaprofen infusion which could have produced this
transient effect. The sulindac group of animals had a lower set
(P < 0.05) of mean pressures, but followed the same pattern
during hemorrhage as the other groups.
Effects of hemorrhage on renal hemodynamics (Table 2)
As shown in Table 2, this amount of hemorrhage resulted in
a 46% decline in GFR and a 38% decline in RBF in control dogs.
Indomethacin-treated dogs had a 58% fall in GFR and an 82%
486 Henrich et a!
Table 1. Effects of hemorrhage on systemic hemodynamics
Mean blood pressure, mm Hg Heart rate, min'
C DI H PC C DI H PC
Control (N = 5)
Mean 139 140 116 138 132 123 160 126
SE 6 5 9 3 12 21 22 6
P NS <0.001 <0.001 NS <0.05 <0.05
Indomethacin (N = 5)
Mean 142 144 116 143 145 129 139 106
SE 9 9 9 5 2 12 6 22
P NS <0.01 <0.01 NS NS NS
Benoxaprofen (N = 5)
Mean 118 150 115 150 116 100 102 84
SE 6 14 10 17 20 8 20 12
P <0.05 <0.01 <0.01 <0.05 NS <0.05
Sulindac (N = 5)
Mean 105 113 91 115 126 114 126 103
SE 6 7 5 3 3 6 4 4
P NS <0.005 <0.005 NS NS <0.05
Abbreviations are: C, control period; DI, post-drug infusion period; H, hemorrhage period; PC, post-control period.
Table 2. Effects of hemorrhage on renal hemodynamics
GFR, mi/mm RBF, mi/mm RVR, u
C DI H PC C DI H PC C DI H PC
Control
Mean 51 56 30 41 316 380 237 252 .46 .38 2.2 .71
SE 9 6 9 5 23 47 44 89 .04 .03 2.0 .13
P NS <0.01 <0.05 NS <0.01 NS NS <0.001 <0.05
Indomethacin
Mean 42 38 l6 35 290 250 46" l29 .56 .76 7,01" 1.57
SE 2 3 5 5 17 13 20 22 .04 .05 2.8 .55
P NS <0.01 <0.01 NS <0.001 <0.001 <0.05 <0.001 <0.001
Benoxaprofen
Mean 40 43 l9 27 303 146b 45b 172 .55 l.315ac 434b 59a
SE 5 8 4 4 26 25 12 59 .07 .35 1.3 .6
P NS <0.001 <0.05 <0.01 <0.001 <0.001 <0.05 <0.005 <0.01
Sulindac
Mean 40 40 16 35 228a 223 57" l79 .56 .61 3.40a .84
SE 5 4 4 4 42 36 16 41 .07 .09 1.04 .13
P NS <0.001 <0.01 NS <0.005 <0.05 NS <0.05 <0.05
Abbreviations same as Table 1.
a p < 0.05 different from control dogs.
b P < 0.01 different from control dogs.
Greater than other drug-treated groups, P < 0.01.
decline in RBF. Both the hemorrhage period GFR (P < 0.05)
and RBF (P < 0.001) were significantly lower than those of the
control group.
Benoxaprofen-treated dogs demonstrated similar results to
the indomethacin group, with one exception. The hemolysis
following benoxaprofen infusion was associated with a 52%
decline in RBF. Hemorrhage further lowered both GFR and
RBF to levels comparable to the indomethacin group of dogs.
Finally, sulindac sulfide-infused dogs also underwent a 60%
reduction in GFR and an even more striking 73% reduction in
RBF. Again, GFR and RBF values in the hemorrhage period
were lower in benoxaprofen- and sulindac-treated animals
compared to controls. The changes in renal vascular resistance
(RVR) depicted in Table 2 also reflect these large changes in
renal blood flow. In each case, the increase in RVR observed in
the hemorrhage period of drug-treated groups was significantly
greater than that in the control animals.
Effects of hemorrhage on arterial and renal venous
concentrations of 6-keto-PGF1a (Table 3)
Hemorrhage resulted in a 2.5-fold increase in the arterial
concentration of 6-keto-PGF,,, and a 3.5-fold increase in renal
venous 6-keto-PGF1c. concentration. Both of these increases
were reversible with reinfusion of the shed blood. In contrast,
indomethacin-treated dogs had a 65% decrease in basal 6-keto-
PGF1a concentrations after the infusion of indomethacin, and
no increase in either arterial or renal venous PGs occurred
during the hemorrhage period. In benoxaprofen-treated dogs,
the concentration of 6-keto-PGF1a increased moderately, but
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Table 3. Effects of hemorrhage on arterial and renal venous concentrations of 6-keto-PGF1a
Arterial 6-keto-PGF1 pg/mi Rena1 venous 6-keto-PGF1a, pg/mi
C DI H PC C DI H PC
Control
Mean 27 28 69 34 18 13 46 20
SE 10 3 10 4 3 3 8 8
P NS <0.01 <0.05 NS <0.001 <0.005
Indomethacin
Mean 15 5.3 63b 10.5 19.9 76b 69b 6.8a
SE .5 .5 .6 2.0 2 2 4 3
P <0.05 NS MS <0.005 NS NS
Benoxaprofen
Mean 26 52 20 22 33 24 13 14
SE 2 6 6 6 8 4 3 4
P NS <0.01 MS NS <0.05 NS
Sulindac
Mean 20 16 12 iia 22 12 12 13
SE 3 5 6 4 5 4 3 4
P NS <0.05 NS <0.05 NS MS
Abbreviations same as Table 1.
a P < 0.05 less than control group.
b P < 0.01 less than control group.
not significantly, in arterial blood only after benoxaprofen. This
change in the arterial concentration may have been related to
hemolysis; however, no increase in renal venous concentra-
tions of 6-keto-PGF1a occurred. Over the next 30 mm, however,
both arterial and renal venous 6-keto-PGF1 concentrations
declined significantly in this benoxaprofen group, failing to
increase with hemorrhage. Sulindac sulfide-treated dogs also
had a significant decline in both arterial and renal venous
concentrations of 6-keto-PGF1a. Thus, in all of the drug-treated
animals, the significant increase in PG production that occurred
in the control dogs during the hemorrhage period was effec-
tively blocked.
Sulindac concentrations in plasma and urine (Table 4)
In sulindac-treated dogs, the concentrations of sulindac sul-
fide increased to 3.69 tg/ml with commencement of the infusion
and remained stable during the hemorrhage period. During
these periods, the sulfide was not detectable in the urine. The
only other sulindac metabolite to increase significantly in the
plasma was sulindac sulfoxide. Trace amounts of the sulfoxide
were also noted in the urine, but neither the sulfide nor sulfone
were detected.
Discussion
These studies demonstrate that plasma concentrations of
sulindac sulfide that approximate the therapeutic range are
capable of enhancing renal ischemia during hemorrhage in a
manner similar to other NSAIDS. This renal ischemic effect
was observed in the absence of a detectable concentration of
the active sulfide in the urine, so that it is unlikely that the
capacity of the kidney to metabolize the sulindac sulfide was
exceeded in these studies. Thus, in this model, inhibition of
renal PG synthesis (as assessed by renal venous 6-keto-PGF1a
concentrations) may occur despite the absence of the sulfide
form in urine. It is of interest to note that the dog converts the
inactive sulfoxide to the active sulfide poorly [39]. Hence
obtaining desired levels of the active metabolite required ad-
Table 4. Sulindac concentrations in plasma and urine, r.sg/ml
C DI H PC
Sulindac suffide
Mean
SE
P
Sulindac sulfoxide
Mean
SE
P
Sulindac sulfone
Mean
SE
P
Sulindac sulfide
Mean
SE
P
Sulindac sulfoxide
Mean
SE
P
Sulindac sulfone
Plasma concentrations, pg/mi
3.50
.72
.35
.06
.05
.03
ND
.55
.17
ND
NS
NS
NS
MS
NS
6.10
2.2
.51
.05
.075
.04
ND
.52
.08
ND
ND 3.69
.62
<0.05 NS
ND .31
.03
<0.05 NS
ND ND
NS
Urine concentrations, jig/mi
ND ND
NS MS
0.0 .24
0.0 .12
NS NS
ND ND
Abbreviation: ND, None detected; remainder same as Table 1.
ministration of an i.v. infusion of the sulfide itself in these
studies. Also of note is the recent report by Miller, Bednar, and
McGiff [281 in which sulindac sulfide was detected in the renal
tissue of rabbits even when the urine was free of sulfide. This
phenomenon of high tissue levels may account for the inhibition
of PG synthesis in the present series of studies.
The development of an NSAID that does not affect renal PG
synthesis would be of obvious benefit. The renal insufficiency
that follows NSAID therapy in high renin states in humans is
most closely correlated with reductions in renal PG synthesis
and release [2, 9]. The hemorrhage model used in the present
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studies provides a rapid ischemic stress that tests the hemody-
namic and PG responses of the kidney and any inhibitory
actions and consequences of the drugs [101. A 20% reduction in
blood pressure was selected based on the reliability and
reversibility of this quantity of hemorrhage. All three NSAIDS
tested in this study were associated with further reductions of
renal perfusion when compared to control values (Table 2). This
reduction is particularly striking and apparent for RBF in the
NSAID-treated groups. In examining the 6-keto-PGF1, data
presented in Table 3, it appears that the failure of PG levels to
increase during the ischemic insult is more important than the
absolute level of PG attained. For example, although dogs
receiving benoxaprofen had a modest increase in PG release
post infusion (possibly related to hemolysis), 6-keto-PGF1,.
levels declined significantly during the hemorrhage period at a
time when an increase in synthesis and release might have
moderated the insult to RBF which was observed. The
prostacyclin metabolite 6-keto-PGF1a was measured because of
the known potent effects of prostacyclin as a vasodilator and
the correlation of endogenous prostacyclin synthesis to renal
hemodynamic changes in the kidney [91. It should be acknowl-
edged that PG excretion rates may be more accurate than renal
venous PG levels as a means of assessing renal PG production
and release.
The exact reasons for the non-renal sparing effect of a low
concentration of sulindac sulfide in this study as compared to
other studies is not readily apparent. One intriguing possibility
is the time course over which renal vasodilatation must occur to
protect RBF. Hemorrhage represents a sudden ischemic stress
requiring a prompt decline in renal vascular resistance to
maintain renal blood flow. In these studies, such a change in
renal vascular resistance was blocked by the three NSAIDS
used and the opposite effect (an increase in RVR) occurred.
Similarly, a report by Nies et al which examined the phenom-
enon of diuretic resistance observed with NSAIDS has pointed
out the importance of renal vasodilatation for a complete
diuretic response [401. This vasodilatation is rapid and, in part,
PG-dependent [40); NSAIDS blunt this vasodilatation and
thereby reduce response [29, 40]. In an earlier study of this
subject, sulindac given orally to humans partly blocked this
diuretic effect [29]. Thus, clinical circumstances in which a
more rapid PG-dependent vasodilatation is required may be
particularly vulnerable to the PG-inhibitory effects of sulindac,
whereas changes that occur more slowly (for instance, in the
setting of underlyuing renal disease) may be less susceptible to
any renal PG-inhibitory effects of sulindac [19—21]. In addition,
species differences and drug distribution may also be factors in
explaining the aggregate results from the literature.
In any case, it seems clear that, while sulindac has provided
the most optimism for a renal-sparing, PG-inhibitory effect by
virtue of its unique metabolism, the present results emphasize
the need for continued caution with the use of this drug, as with
all NSAIDS. It is likely that the rapidity and severity of the
renal ischemic stress as well as the tissue distribution of the
active drug significantly influences the net changes in observed
renal hemodynamics. Other studies which examine these issues
are needed before any NSAID can be conclusively shown to be
devoid of PG-related effects in the kidney.
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